Supplementary Materials

The PDF file includes:

• Materials and Methods
• Fig. S1. Ipilimumab, nivolumab, and pembrolizumab responders and nonresponders with low melanoma neoantigen loads.
• Fig. S2. Characterization of UV2 and UV3 melanoma cell lines.
• Fig. S3. RNA sequencing reveals enhanced cytotoxic activity and upregulation of T cell dysfunction markers in UV2 melanomas compared to parental D4M.3A.3 melanomas.
• Fig. S4. Addition of imiquimod and aFP to immune checkpoint blockade induces an abscopal effect in mice bearing melanomas or pancreatic ductal adenocarcinomas.
• Fig. S5. Combination immunotherapy improves T cell responses and is associated with markers of increased DC infiltration and function.
• Fig. S6. Melanoma treatment with combination immunotherapy promotes melanocyte antigen expression and immune elimination of melanomas, but not pancreatic tumors.
• References (37–44)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

• Data file S1 (Microsoft Excel format). Supplementary tables.
• Data file S2 (Microsoft Excel format). Raw data.